Literature DB >> 20860987

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.

V-F Mautner1, R Nguyen2, R Knecht3, C Bokemeyer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20860987     DOI： 10.1093/annonc/mdq566

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Authors:  Stéphane Goutagny; Eric Raymond; Marina Esposito-Farese; Stéphanie Trunet; Christian Mawrin; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Marco Giovannini; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

3.  Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Authors:  Julia Furtner; Veronika Schöpf; Katharina Seystahl; Emilie Le Rhun; Roberta Rudà; Ulrich Roelcke; Susanne Koeppen; Anna Sophie Berghoff; Christine Marosi; Paul Clement; Marina Faedi; Colin Watts; Wolfgang Wick; Riccardo Soffietti; Michael Weller; Matthias Preusser
Journal:  Neuro Oncol       Date:  2015-09-09       Impact factor: 12.300

Review 4.  Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.

Authors:  Jaishri Blakeley
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2012-10       Impact factor: 2.064

5.  Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2.

Authors:  H A Riina; J-K Burkhardt; A Santillan; L Bassani; A Patsalides; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2012-06-04       Impact factor: 1.610

6.  Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.

Authors:  Said Farschtschi; Philipp Kollmann; Carsten Dalchow; Alexander Stein; Victor-Felix Mautner
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-21       Impact factor: 2.503

7.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

8.  Antiangiogenic agents for nonmalignant brain tumors.

Authors:  Ammar H Hawasli; Joshua B Rubin; David D Tran; Douglas R Adkins; Shahid Waheed; Timothy E Hullar; David H Gutmann; John Evans; Jeffrey R Leonard; Gregory J Zipfel; Michael R Chicoine
Journal:  J Neurol Surg B Skull Base       Date:  2013-03-13

9.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

10.  Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.

Authors:  Pengfei Liu; Qingyu Yao; N A Li; Yongliang Liu; Yuguo Wang; Meng Li; Zefu Li; Jianmin Li; Gang Li
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.